Literature DB >> 23839029

Comparison of a drug versus money and drug versus drug self-administration choice procedure with oxycodone and morphine in opioid addicts.

Sandra D Comer1, Verena E Metz, Ziva D Cooper, William J Kowalczyk, Jermaine D Jones, Maria A Sullivan, Jeanne M Manubay, Suzanne K Vosburg, Mary E Smith, Deena Peyser, Phillip A Saccone.   

Abstract

This double-blind, placebo-controlled study investigated the effects of oral morphine (0, 45, 135 mg/70 kg) and oral oxycodone (0, 15, 45 mg/70 kg) on buprenorphine-maintained opioid addicts. As a 3: 1 morphine : oxycodone oral dose ratio yielded equivalent subjective and physiological effects in nondependent individuals, this ratio was used in the present study. Two self-administration laboratory procedures - that is, a drug versus money and a drug versus drug procedure - were assessed. Study participants (N=12) lived in the hospital and were maintained on 4 mg/day sublingual buprenorphine. When participants chose between drug and money, money was preferred over all drug doses; only high-dose oxycodone was self-administered more than placebo. When participants chose between drug and drug, both drugs were chosen more than placebo, high doses of each drug were chosen over low doses, and high-dose oxycodone was preferred over high-dose morphine. The subjective, performance-impairing, and miotic effects of high-dose oxycodone were generally greater than those of high-dose morphine. The study demonstrated that a 3: 1 oral dose ratio of morphine : oxycodone was not equipotent in buprenorphine-dependent individuals. Both self-administration procedures were effective for assessing the relative reinforcing effects of drugs; preference for one procedure should be driven by the specific research question of interest.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23839029      PMCID: PMC4056333          DOI: 10.1097/FBP.0b013e328363d1c4

Source DB:  PubMed          Journal:  Behav Pharmacol        ISSN: 0955-8810            Impact factor:   2.293


  21 in total

Review 1.  How different is oxycodone from morphine?

Authors:  Eija Kalso
Journal:  Pain       Date:  2007-10-24       Impact factor: 6.961

2.  Blood-brain barrier transport helps to explain discrepancies in in vivo potency between oxycodone and morphine.

Authors:  Emma Boström; Margareta Hammarlund-Udenaes; Ulrika S H Simonsson
Journal:  Anesthesiology       Date:  2008-03       Impact factor: 7.892

Review 3.  Buprenorphine: new tricks with an old molecule for pain management.

Authors:  Howard A Heit; Douglas L Gourlay
Journal:  Clin J Pain       Date:  2008-02       Impact factor: 3.442

4.  Integrating nine prescription opioid analgesics and/or four signal detection systems to summarize statewide prescription drug abuse in the United States in 2007.

Authors:  Michael F Schneider; J Elise Bailey; Theodore J Cicero; Richard C Dart; James A Inciardi; Mark Parrino; Alvaro Muñoz
Journal:  Pharmacoepidemiol Drug Saf       Date:  2009-09       Impact factor: 2.890

5.  Choice between money and intranasal heroin in morphine-maintained humans.

Authors:  S D Comer; E D Collins; M W Fischman
Journal:  Behav Pharmacol       Date:  1997-12       Impact factor: 2.293

6.  Comparison of intravenous and intranasal heroin self-administration by morphine-maintained humans.

Authors:  S D Comer; E D Collins; R B MacArthur; M W Fischman
Journal:  Psychopharmacology (Berl)       Date:  1999-04       Impact factor: 4.530

7.  Intravenous oxycodone, hydrocodone, and morphine in recreational opioid users: abuse potential and relative potencies.

Authors:  William W Stoops; Kevin W Hatton; Michelle R Lofwall; Paul A Nuzzo; Sharon L Walsh
Journal:  Psychopharmacology (Berl)       Date:  2010-07-28       Impact factor: 4.530

Review 8.  Self-administration of cocaine, cannabis and heroin in the human laboratory: benefits and pitfalls.

Authors:  Margaret Haney
Journal:  Addict Biol       Date:  2008-10-09       Impact factor: 4.280

9.  Within-subject comparison of the psychopharmacological profiles of oral oxycodone and oral morphine in non-drug-abusing volunteers.

Authors:  James P Zacny; Stephanie A Lichtor
Journal:  Psychopharmacology (Berl)       Date:  2007-09-27       Impact factor: 4.530

10.  Abuse liability of prescription opioids compared to heroin in morphine-maintained heroin abusers.

Authors:  Sandra D Comer; Maria A Sullivan; Robert A Whittington; Suzanne K Vosburg; William J Kowalczyk
Journal:  Neuropsychopharmacology       Date:  2007-06-20       Impact factor: 7.853

View more
  11 in total

1.  Additive and subadditive antiallodynic interactions between μ-opioid agonists and N-methyl D-aspartate antagonists in male rhesus monkeys.

Authors:  Jeremy C Cornelissen; Floyd F Steele; Kenner C Rice; Katherine L Nicholson; Matthew L Banks
Journal:  Behav Pharmacol       Date:  2018-02       Impact factor: 2.293

2.  Impact of co-administration of oxycodone and smoked cannabis on analgesia and abuse liability.

Authors:  Ziva D Cooper; Gillinder Bedi; Divya Ramesh; Rebecca Balter; Sandra D Comer; Margaret Haney
Journal:  Neuropsychopharmacology       Date:  2018-02-05       Impact factor: 7.853

3.  Sex differences in opioid reinforcement under a fentanyl vs. food choice procedure in rats.

Authors:  E Andrew Townsend; S Stevens Negus; S Barak Caine; Morgane Thomsen; Matthew L Banks
Journal:  Neuropsychopharmacology       Date:  2019-02-28       Impact factor: 7.853

4.  Oxycodone-Mediated Activation of the Mu Opioid Receptor Reduces Whole Brain Functional Connectivity in Mice.

Authors:  Md Taufiq Nasseef; Jai Puneet Singh; Aliza T Ehrlich; Michael McNicholas; Da Woon Park; Weiya Ma; Praveen Kulkarni; Brigitte L Kieffer; Emmanuel Darcq
Journal:  ACS Pharmacol Transl Sci       Date:  2019-06-28

Review 5.  Insights from Preclinical Choice Models on Treating Drug Addiction.

Authors:  Matthew L Banks; S Stevens Negus
Journal:  Trends Pharmacol Sci       Date:  2016-12-02       Impact factor: 14.819

6.  Methamphetamine administration dose effects on sexual desire, sexual decision making, and delay discounting.

Authors:  Meredith S Berry; Natalie R Bruner; Evan S Herrmann; Patrick S Johnson; Matthew W Johnson
Journal:  Exp Clin Psychopharmacol       Date:  2020-09-28       Impact factor: 3.157

Review 7.  Clinical models of decision making in addiction.

Authors:  Mikhail N Koffarnus; Brent A Kaplan
Journal:  Pharmacol Biochem Behav       Date:  2017-08-26       Impact factor: 3.533

8.  Rapid dopamine transmission within the nucleus accumbens: dramatic difference between morphine and oxycodone delivery.

Authors:  Caitlin M Vander Weele; Kirsten A Porter-Stransky; Omar S Mabrouk; Vedran Lovic; Bryan F Singer; Robert T Kennedy; Brandon J Aragona
Journal:  Eur J Neurosci       Date:  2014-09-11       Impact factor: 3.386

9.  BOLD Imaging in Awake Wild-Type and Mu-Opioid Receptor Knock-Out Mice Reveals On-Target Activation Maps in Response to Oxycodone.

Authors:  Kelsey Moore; Dan Madularu; Sade Iriah; Jason R Yee; Praveen Kulkarni; Emmanuel Darcq; Brigitte L Kieffer; Craig F Ferris
Journal:  Front Neurosci       Date:  2016-11-03       Impact factor: 4.677

10.  Relative Bioavailability, Intranasal Abuse Potential, and Safety of Benzhydrocodone/Acetaminophen Compared with Hydrocodone Bitartrate/Acetaminophen in Recreational Drug Abusers.

Authors:  Sven M Guenther; Travis C Mickle; Andrew C Barrett; Kathryn Ann Roupe; Jing Zhou; Vincent Lam
Journal:  Pain Med       Date:  2018-05-01       Impact factor: 3.750

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.